NRAS and Miyoshi myopathy: Using targeted NGS approaches, KRAS mutations were detected in 17% of pPCL, 18% of sPCL, and 33% of MM, and NRAS mutations in 4% of pPCL, 36% of sPCL, and 27% of MM [30].